COVID-19 Youth Ambassador Corp, a Community-based Program to Address Vaccine Hesitancy

With over one million confirmed deaths from COVID-19, the United States (U.S.) continues to battle the public health crisis arising from the spread of the SARS-CoV-2 virus. The COVID-19 pandemic has had a devastating impact on our economic, social, and health systems. Social distancing efforts and other precautionary measures such as mask-wearing have not sufficiently reduced morbidity and mortality from COVID-19; thus, COVID-19 vaccinations are an important tool for substantially alleviating the effects of the pandemic. Although COVID-19 vaccines are available to all Americans aged six months and older, many individuals are hesitant to receive vaccines. The two most common reasons for vaccine hesitancy are some individuals do not think the vaccine is safe and some believe it’s not effective. Vaccine hesitancy is more common among disadvantaged communities of color and Latinos. In order to decrease vaccine hesitancy, the government and larger healthcare agencies must invest in local community-based programs. These organizations play an important role in educating hard-to-reach and vulnerable communities to deliver factual and scientific information in a culturally appropriate manner. This capstone paper addresses the role of community based organizations to increase vaccine confidence. Specifically, a COVID-19 youth ambassador corps program is being implemented at Health Education Council (HEC), a non-profit organization based in South Sacramento, to recruit trainees from target communities to provide scientific and evidenced- based education on COVID-19 vaccination. HEC utilized funding from a local Medicaid Managed Care Plan, Partnership Health Plan’s (PHP’s) COVID19 Community Grant Incentives program to target the unvaccinated population in PHC’s Medi-Cal service region. Using principles from HEC’s Peers Helping Peers Program, HEC created and launched a “Youth Vaccine Ambassador Corps\u27\u27 which mobilized and trained local PHC/Medi-Cal youth ages 17-24 to develop and share pro-vaccine messages to educate their local community

Fragile X syndrome: A review of clinical management

The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5' untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance

Fragile X syndrome: A review of clinical management

The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5′ untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance

Warburg effect linked to cognitive-executive deficits in FMR1 premutation.

A 55-200 CGG repeat expansion in the 5'-UTR of the fragile X mental retardation 1 (FMR1) gene is known as a premutation. Some carriers are affected by the neurodegenerative disorder fragile X-associated tremor/ataxia syndrome (FXTAS), primary ovarian insufficiency, and neurobehavioral impairments. Based on the mitochondrial dysfunction observed in fibroblasts and brain samples from carriers, as well as in neurons and brains from a mouse model of the premutation, we evaluated the presence of the Warburg effect in peripheral blood mononuclear cells (PBMCs) from 30 premutation carriers with either a rebalance of the metabolism [increasing glycolysis while decreasing oxidative phosphorylation (oxphos)] or a metabolic amplification (increasing glycolysis while maintaining/increasing oxphos). Deficits in oxphos-more pronounced in FXTAS-affected subjects-were accompanied by a shift toward glycolysis, suggesting increased glycolysis despite aerobic conditions. Differential proteomics extended these findings, unveiling a decreased antioxidant response, translation, and disrupted extracellular matrix and cytoskeleton organization with activation of prosenescence pathways. Lower bioenergetics segregated with increased incidence of low executive function, tremors, below-average IQ, and FXTAS. The combination of functional and proteomic data unveiled new mechanisms related to energy production in the premutation, showing the potential of being applicable to other psychiatric disorders to identify endophenotype-specific responses relevant to neurobiology.-Napoli, E., Song, G., Schneider, A., Hagerman, R., Eldeeb, M. A. A. A., Azarang, A., Tassone, F., Giulivi, C. Warburg effect linked to cognitive-executive deficits in FMR1 premutation